at labeling concentrations, it is widely preferred for in vivo studies of cancer cell proliferation. However, at radiosensitizing concentrations, BrdU becomes myelosuppressive, thus limiting its use for radiosensitizing.

BrdU differs from thymidine in that BrdU substitutes a bromine atom for thymidine's CH₃ group. The Br substitution can be used in